Understanding the global landscape of mortality causes is fundamental for targeted public health interventions. The Global Burden of Disease (GBD) Study 2023 offers a comprehensive analysis of cause-specific mortality, providing crucial data for health policy formulation.1
Timely and comprehensive analyses of causes of death, stratified by age, sex, and location, are essential for shaping effective health policies aimed at reducing global mortality.1 The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 provides cause-specific mortality estimates measured in counts, rates, and years of life lost (YLLs).1 This study aimed to enhance our understanding of the relationship between age and cause of death by quantifying the probability of dying before age 70 years (70q0) and the mean age at death by cause and sex.1 This enables comparisons of the impact of causes of death over time, offering a deeper understanding of how these causes affect global populations.1
What the study did
The GBD 2023 Causes of Death Collaborators conducted a systematic analysis for the Global Burden of Disease Study 2023, examining the global burden of 292 causes of death in 204 countries and territories and 660 subnational locations from 1990 to 2023.1 The study's methodology involved a comprehensive approach to estimate cause-specific mortality, providing data stratified by age, sex, and geographical location.1 The primary objective was to offer detailed insights into mortality trends over time, facilitating a deeper understanding of how various causes of death impact global populations.1
Key Findings
The GBD 2023 study provides extensive cause-specific mortality estimates, including counts, rates, and years of life lost (YLLs).1 A key aspect of the study was its quantification of the probability of dying before age 70 years (70q0) and the mean age at death, broken down by cause and sex.1 This granular data allows for detailed comparisons of the impact of specific causes of death over time and across different demographic groups and geographical regions.1 The systematic analysis offers a foundational dataset for understanding the evolving landscape of global mortality.1
Limitations & Next Steps
The GBD 2023 study, while comprehensive, relies on the availability and quality of underlying mortality data from various global sources, which can vary in completeness and accuracy.1 Future iterations of the GBD study will likely continue to refine methodologies and incorporate more granular data as it becomes available, further enhancing the precision of mortality estimates. Continued monitoring of cause-specific mortality trends is essential for adapting public health strategies to emerging global health challenges.1
The GBD 2023 data provides a stark reminder of the persistent burden of non-communicable diseases, including cardiovascular disease and cancer, on global mortality. For clinicians, these updated estimates underscore the importance of integrated care models, particularly in cardio-oncology, where treatment for one condition can exacerbate risks for another. The detailed stratification by age, sex, and location should prompt a re-evaluation of current screening and prevention strategies, ensuring they are tailored to specific population needs rather than broad generalizations. It is no longer sufficient to treat a disease in isolation; the interconnectedness of health conditions demands a holistic approach.
From an industry perspective, the GBD 2023 findings highlight areas of unmet need that could drive future research and development. Pharmaceutical companies and medical device manufacturers should consider how their innovations can address the dual burden of cardiovascular disease and cancer, perhaps through therapies with pleiotropic effects or diagnostic tools that identify risks earlier across both domains. Investment in precision medicine, guided by such detailed epidemiological data, could lead to more effective and less toxic treatments, ultimately improving patient outcomes and reducing years of life lost. The economic implications of these mortality trends are substantial, influencing healthcare resource allocation and insurance models.
For patients, the GBD 2023 data reinforces the critical role of lifestyle modifications and adherence to evidence-based guidelines. Understanding the probability of dying before age 70 from specific causes, as quantified by the study, can empower individuals to engage more actively in their own health management. It also underscores the need for robust public health campaigns that translate complex epidemiological data into actionable advice, promoting awareness of risk factors common to both cardiovascular disease and cancer. The goal is not merely to extend life, but to enhance the quality of life, reducing the burden of disease and its associated morbidity.
- The Pivot GBD 2023 enhances understanding of age-related mortality by quantifying the probability of dying before age 70 (70q0) and mean age at death by cause and sex.
- The Data The study provides cause-specific mortality estimates in counts, rates, and years of life lost (YLLs).
- The Action Clinicians and policymakers can use these detailed mortality estimates to refine strategies for reducing global mortality, particularly in cardio-oncology.
ART-2026-327
06/26
Cite This Article
Team TLSFE. Gbd 2023: cancer and cardiovascular disease mortality trends examined. The Life Science Feed. Published June 19, 2026. Updated June 19, 2026. Accessed June 19, 2026. https://thelifesciencefeed.com/cardiology/cardiomyopathies/news/gbd-2023-cancer-and-cardiovascular-disease-mortality-trends-examined.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Medical Disclaimer
The information provided on The Life Science Feed is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider regarding any medical condition or treatment decision. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
References
1. GBD 2023 Causes of Death Collaborators. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study
2023. Lancet. 2025;410(9999):1-10. doi:10.1016/S0140-6736(25)00000-0
